Featured Education

The Evolution of HCT

Click here to learn more

On Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
GVHD 5 - ECHO Program: Atypical Manifestations of Chronic GVHD
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care. The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients. Questions and comments from the learners will be encouraged to facilitate discussion.
The Evolution of HCT, Part 3: Donor Availability
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Personalizing Treatment Options Across the Continuum of MDS and sAML
The number of approved drugs for myelodysplastic syndromes (MDS) is limited, and not all agents have been shown to be highly efficacious and to improve survival. However, the oncology community witnessed an explosion of new agents and investigational approaches in 2020 that has persisted until today. In this virtual symposium hear expert insights regarding the role of cytogenetic abnormalities, new prognostic models, and other patient- and disease-related factors in diagnosis, prognosis, and treatment planning for individuals with MDS. Faculty will also assess the clinical implications of recent and emerging safety and efficacy data for novel agents and combinations and provide strategies for effective communication with patients, including those in special populations and those of diverse backgrounds, to manage symptoms and enhance quality of life. This virtual Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
The Evolution of HCT, Part 2: Eligibility
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 2 in a 5-part series, covering advances that have expanded eligibility for HCT and considerations for who is a candidate.
Potential Benefits of Incretins Beyond Glycemic Control in T2D
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs.  What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. This taped satellite symposium was derived from the 58th EASD Annual Meeting on September 19, 2022.
The Evolution of HCT, Part 4: Addressing Barriers
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 4 in a 5-part series, examining major barriers to HCT and ways to overcome them.